MX363258B - Compuestos piridinilpirazoloquinolina. - Google Patents

Compuestos piridinilpirazoloquinolina.

Info

Publication number
MX363258B
MX363258B MX2015013446A MX2015013446A MX363258B MX 363258 B MX363258 B MX 363258B MX 2015013446 A MX2015013446 A MX 2015013446A MX 2015013446 A MX2015013446 A MX 2015013446A MX 363258 B MX363258 B MX 363258B
Authority
MX
Mexico
Prior art keywords
formula
compound
pyridinylpyrazoloquinoline
group
represented
Prior art date
Application number
MX2015013446A
Other languages
English (en)
Other versions
MX2015013446A (es
Inventor
Norimine Yoshihiko
Takeda Kunitoshi
Ishihara Yuki
Sato Nobuaki
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2015013446A publication Critical patent/MX2015013446A/es
Publication of MX363258B publication Critical patent/MX363258B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un compuesto representado por la fórmula (I), o una sal farmacéuticamente aceptable del mismo: (ver Fórmula) donde R1 es un grupo representado por la fórmula: (ver Fórmula) un grupo representado por la fórmula: (ver Fórmula) o un grupo representado por la fórmula: (ver Fórmula) y R2 es un grupo 3-metiltetrahidro-2H-piran-4-ilo o un grupo 4-metoxiciclohexilo.
MX2015013446A 2013-04-05 2014-04-03 Compuestos piridinilpirazoloquinolina. MX363258B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361809118P 2013-04-05 2013-04-05
US201361809095P 2013-04-05 2013-04-05
PCT/JP2014/059852 WO2014163146A1 (ja) 2013-04-05 2014-04-03 ピリジニルピラゾロキノリン化合物

Publications (2)

Publication Number Publication Date
MX2015013446A MX2015013446A (es) 2016-01-12
MX363258B true MX363258B (es) 2019-03-19

Family

ID=51658437

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015013446A MX363258B (es) 2013-04-05 2014-04-03 Compuestos piridinilpirazoloquinolina.

Country Status (20)

Country Link
US (1) US9550776B2 (es)
EP (1) EP2982674B1 (es)
JP (1) JP6244353B2 (es)
KR (1) KR102234131B1 (es)
CN (1) CN105189496B (es)
AU (1) AU2014250391B2 (es)
BR (1) BR112015024075B1 (es)
CA (1) CA2904820C (es)
CL (1) CL2015002837A1 (es)
ES (1) ES2654094T3 (es)
HK (1) HK1219100A1 (es)
IL (1) IL241695B (es)
MX (1) MX363258B (es)
PE (1) PE20151718A1 (es)
PH (1) PH12015502178A1 (es)
RU (1) RU2655172C2 (es)
SG (1) SG11201507733YA (es)
TW (1) TW201439091A (es)
WO (1) WO2014163146A1 (es)
ZA (1) ZA201507044B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201406486D0 (en) 2014-04-10 2014-05-28 Redx Pharma Ltd Antibacterial compounds
WO2017046606A1 (en) * 2015-09-18 2017-03-23 Redx Pharma Plc Antibacterial compounds
BR112019023552A2 (pt) 2017-06-01 2020-06-02 Eisai R&D Management Co., Ltd. Agente terapêutico para a demência com corpos de lewy contendo derivado de pirazoloquinolina
CA3075892C (en) 2017-09-14 2024-01-23 Daiichi Sankyo Company, Limited Heterocyclic compounds for the treatment and/or prevention of inflammatory diseases
WO2021150613A1 (en) 2020-01-20 2021-07-29 Incyte Corporation Spiro compounds as inhibitors of kras
US11739102B2 (en) 2020-05-13 2023-08-29 Incyte Corporation Fused pyrimidine compounds as KRAS inhibitors
US11999752B2 (en) 2020-08-28 2024-06-04 Incyte Corporation Vinyl imidazole compounds as inhibitors of KRAS
WO2022072783A1 (en) 2020-10-02 2022-04-07 Incyte Corporation Bicyclic dione compounds as inhibitors of kras
WO2022204112A1 (en) 2021-03-22 2022-09-29 Incyte Corporation Imidazole and triazole kras inhibitors
MX2024000357A (es) 2021-07-07 2024-02-12 Incyte Corp Compuestos triciclicos como inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras).
US12600717B2 (en) 2021-07-14 2026-04-14 Incyte Corporation Tricyclic compounds as inhibitors of KRAS
US12441742B2 (en) 2021-08-31 2025-10-14 Incyte Corporation Naphthyridine compounds as inhibitors of KRAS
WO2023049697A1 (en) 2021-09-21 2023-03-30 Incyte Corporation Hetero-tricyclic compounds as inhibitors of kras
CA3234375A1 (en) 2021-10-01 2023-04-06 Incyte Corporation Pyrazoloquinoline kras inhibitors
WO2023064857A1 (en) 2021-10-14 2023-04-20 Incyte Corporation Quinoline compounds as inhibitors of kras

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05132484A (ja) 1991-04-26 1993-05-28 Otsuka Pharmaceut Factory Inc ピラゾロキノリン及びピラゾロナフチリジン誘導体
DK0760819T3 (da) 1994-05-24 2000-10-09 Hoffmann La Roche Tricykliske dicarbonylderivater
DE102004004142A1 (de) * 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Cyclylmethyl- und 6-Alkylmethyl-substituierte Pyrazolopyrimidine
WO2005118583A1 (en) 2004-05-28 2005-12-15 Millennium Pharmaceuticals, Inc. 2, 5-dihydro-pyrazolo`4, 3-c!quinolin-4-ones as chk-1 inhibitors
JP2006045118A (ja) 2004-08-04 2006-02-16 Mochida Pharmaceut Co Ltd 新規ピラゾロキノロン誘導体
CA2622605A1 (en) 2005-09-15 2007-03-22 Aska Pharmaceutical Co., Ltd. Heterocycle compound, and production process and application thereof
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
CA2671980C (en) 2006-12-13 2015-05-05 Aska Pharmaceutical Co., Ltd. Quinoxaline derivatives
PT2152712E (pt) 2007-05-11 2012-02-29 Pfizer Compostos amino-heterocíclicos
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
WO2010101230A1 (ja) * 2009-03-05 2010-09-10 アステラス製薬株式会社 キノキサリン化合物
PE20120505A1 (es) 2009-03-31 2012-05-09 Boehringer Ingelheim Int Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona como moduladores de pde9a
RS54834B1 (sr) * 2010-09-07 2016-10-31 Astellas Pharma Inc Jedinjenja pirazolokvinolina
PT2573073E (pt) * 2011-09-26 2015-02-05 Sanofi Sa Derivados de pirazoloquinolinona, sua preparação e sua utilização terapêutica
JP6042060B2 (ja) 2011-09-26 2016-12-14 サノフイ ピラゾロキノリノン誘導体、その調製および治療上の使用
WO2013051639A1 (ja) * 2011-10-07 2013-04-11 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロキノリン誘導体

Also Published As

Publication number Publication date
EP2982674A1 (en) 2016-02-10
EP2982674B1 (en) 2017-10-25
JP6244353B2 (ja) 2017-12-06
BR112015024075A2 (pt) 2017-10-24
CN105189496B (zh) 2017-03-29
CL2015002837A1 (es) 2016-04-22
RU2015140669A3 (es) 2018-03-21
JPWO2014163146A1 (ja) 2017-02-16
ZA201507044B (en) 2017-02-22
US20160289225A1 (en) 2016-10-06
BR112015024075B1 (pt) 2022-05-03
AU2014250391B2 (en) 2017-11-02
PH12015502178A1 (en) 2016-01-25
US9550776B2 (en) 2017-01-24
CN105189496A (zh) 2015-12-23
IL241695B (en) 2019-06-30
CA2904820A1 (en) 2014-10-09
MX2015013446A (es) 2016-01-12
CA2904820C (en) 2021-05-18
TW201439091A (zh) 2014-10-16
PE20151718A1 (es) 2015-11-22
KR102234131B1 (ko) 2021-04-01
WO2014163146A1 (ja) 2014-10-09
SG11201507733YA (en) 2015-10-29
AU2014250391A1 (en) 2015-10-15
EP2982674A4 (en) 2016-08-31
RU2015140669A (ru) 2017-05-11
RU2655172C2 (ru) 2018-05-24
ES2654094T3 (es) 2018-02-12
KR20150138204A (ko) 2015-12-09
HK1219100A1 (en) 2017-03-24

Similar Documents

Publication Publication Date Title
PH12015502178A1 (en) Pyridinylpyrazoloquinoline compound
PH12015501993A1 (en) Pyrazole-amide compound and medicinal uses therefor
MX2013012542A (es) Compuestos de amida y aplicacion farmaceutica para el mismo.
IN2015DN01035A (es)
UA116395C2 (uk) ПОХІДНІ ТРИАЗОЛ[4,5-b]ПІРИМІДИНУ
PH12014500444A1 (en) Pyrazole compound and pharmaceutical use thereof
MY163187A (en) Novel imidazo-oxazine compound or salt thereof
MX2015002040A (es) Baricitinib deuterado.
UA118666C2 (uk) Похідні піразолу
PH12015500900B1 (en) A stabilized pemetrexed formulation
PH12015501588B1 (en) Compounds and methods for treating bacterial infections
MX2016009794A (es) Derivado de sulfonamida heterociclico y medicina que comprende el mismo.
UA115357C2 (uk) Похідні піридин-4-ілу
PH12015502665A1 (en) Improvements in or relating to organic compounds
MY162886A (en) Novel tetrahydropyridopyrimidine compound or salt thereof
PH12017501071B1 (en) Dihydropyrimidin-2-one compounds and medical use thereof
MX2015015755A (es) Derivados de perhidroquinoxalina utiles como analgesicos.
PH12015501146A1 (en) Hydantoin derivative
IN2014DN10669A (es)
MX363458B (es) Nuevos derivados de tetrazolona.
IN2014DE01203A (es)
UA88023U (ru) Соединение 1,3-бис-(2-гидроксиэтил)-урацил с потенциальными физиологическими свойствами
UA87650U (uk) Сполука 1-(1',1'-дифтор-2'-бром-2'-хлоретил)-5-метилурацил з потенційними фізіологічними властивостями
UA87694U (uk) Сполука 4,5,6,7-тетрагідро-3н-2-n-(пара-метоксифенациламіно)-азепіну гідрохлорид з потенційними фізіологічними властивостями